Covalent Bruton tyrosine kinase inhibitors (cBTKis) have played a significant role in the management of several B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.